• 2017, CRODA International PLC acquired part of the patent portfolio covering the use of adjuvants for Vaccine applications.
• CRODA International PLC has manufacturing rights to the product in question.
• These types of particles (ISCOM) have been commercialized in Novavax Inc.´s Covid vaccine, NVX-CoV2373.

Our In-vitro studies have identified three saponin-based formulations and have demonstrated efficacy against solid and non-solid cancer tumors